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Objective: The value and cost-effectiveness of less invasive alternative imaging (AI) modalities (duplex ultrasound scanning,
computed tomography angiography, and magnetic resonance angiography) in the care of peripheral arterial disease (PAD)
has been reported; however, there is no consensus on their role. We hypothesized that AI utilization is low compared with
angiography in the United States and that patient and hospital characteristics are both associated with AI utilization.
Methods: The Nationwide Inpatient Sample (2007-2010) was used to identify patients with an International Classiﬁcation
of Diseases-Ninth Edition diagnosis of claudication or critical limb ischemia (CLI) as well as PAD treatment (surgical,
endovascular, or amputation). Patients with AI and those with angiography or expected angiography (endovascular
procedures without imaging codes) were selected and compared. Multivariable logistic regression was performed for
receiving AI stratiﬁed by claudication and CLI and adjusting for patient and hospital factors.
Results:We identiﬁed 290,184 PAD patients, of whom 5702 (2.0%) received AI. Patients with AI were more likely to have
diagnosis of CLI (78.8% vs 48.6%; P < .0001) and receive open revascularizations (30.4% vs 18.8%; P < .0001). Van
Walraven comorbidity scores (mean [standard error] 5.85 6 0.22 vs 4.10 6 0.05; P < .0001) reﬂected a higher co-
morbidity burden in AI patients. In multivariable analysis for claudicant patients, AI was associated with large bed size
(odds ratio [OR], 3.26, 95% conﬁdence interval [CI], 1.16-9.18; P[ .025), teaching hospitals (OR, 1.97; 95% CI, 1.10-
3.52; P [ .023), and renal failure (OR, 1.52; 95% CI, 1.13-2.05; P [ .006). For CLI patients, AI was associated with
black race (OR, 1.53; 95% CI, 1.13-2.08; P[ .006) and chronic heart failure (OR, 1.29; 95% CI, 1.04-1.60; P[ .021)
and was negatively associated with renal failure (OR, 0.80; 95% CI, 0.67-0.95; P [ .012). The Northeast and West
regions were associated with higher odds of AI in claudicant patients (OR, 2.41; 95% CI, 1.23-4.75; P[ .011; and OR,
2.59; 95% CI, 1.34-5.02; P [ .005, respectively) and CLI patients (OR, 4.31; 95% CI, 2.20-8.36; P < .0001; and OR,
2.18; 95% CI, 1.12-4.22; P [ .021, respectively). Rates of AI utilization across states were not evenly distributed but
showed great variability, with ranges from 0.31% to 9.81%.
Conclusions: National utilization of AI for PAD is low and shows great variation among institutions in the United States.
Patient and hospital factors are both associated with receiving AI in PAD care, and AI utilization is subject to signiﬁcant
regional variation. These ﬁndings suggest differences in systems of care or practice patterns and call for a clearer un-
derstanding and a more uniﬁed approach to imaging strategies in PAD care. (J Vasc Surg 2014;59:1315-22.)For patients with peripheral arterial disease (PAD),
adequate imaging of the arterial vasculature is required to
formulate a treatment strategy.1 Several imaging modalities
can be used to assist decision making between endovascu-
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(AI) modalities of computed tomography angiography
(CTA), duplex ultrasound scanning (DUS), or magnetic
resonance angiography (MRA).
Percutaneous angiography has been the conventional
imaging method for PAD evaluation for many years but
is associated with higher costs and local and systemic com-
plications, including hemorrhage, contrast-induced ne-
phropathy, or even anaphylactic shock.2-4 In response, AI
modalities have been assessed for accuracy and their value
in decision making for treatment planning. Several studies
in recent decades have compared merits and limitations
of the available imaging in PAD care.3,5-10 Particularly in
Europe, the evolving role of AI is well described because
these noninvasive techniques have come to replace conven-
tional angiography in many institutions.11-14
DUS is a safe modality because it allows for hemody-
namic PAD evaluation, is safe and inexpensive, and is reli-
able and useful for clinical decision making.2,14-17 The
operator-dependency and lack of a true road-map image
are disadvantages described for DUS; therefore, a skilled
technician is required, and mapping the results on an arte-
rial map is recommended.2,7,15,18 Therapeutic conﬁdence1315
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the other modalities.9 MRA and CTA have also been advo-
cated as viable, very accurate, and cost-effective alternatives
to angiography.2,9,10,17,19 Although less invasive than angio-
graphy, CTA and MRA are both associated with systemic
risks due to the contrast or ionizing radiation used in these
modalities.19
AI modalities have been well studied, but results and
conclusions are often varied, leading to varying diagnostic
approaches in PAD and a lack of national and international
consensus. In addition to clinical factors, local factors, such
as practice cultures, provider preferences, local resources,
and expertise, likely affect diagnostic strategy.12 This study
used the Nationwide Inpatient Sample (NIS) database to
determine differences in the utilization of AI compared
with conventional angiography in the U.S. We hypothe-
sized that AI is infrequently used despite existing evidence
of its beneﬁts and that imaging utilization differs by patient
as well as by institutional characteristics.
METHODS
Data source and study cohort. We used discharge
data from the most recent available years (2007-2010) of
the NIS, developed as part of the Healthcare Cost and
Utilization Project (HCUP), sponsored by the Agency
for Healthcare Research and Quality.20 This is the largest
publicly available all-payer inpatient care database in the
United States, and the selected time frame contains data
from 45 states. NIS data are weighted to represent w90%
of all hospital and discharges nationally. NIS weight factors
are constructed to allow for correction for the survey’s
complex sample design and possible oversampling of dis-
charges from a certain hospital type or region.21,22 Patients
in our cohort were selected by using International Classi-
ﬁcation of Disease-Ninth Edition (ICD-9) codes for
revascularization and amputation procedures with primary
and secondary diagnostic codes for PAD, either claudica-
tion or critical limb ischemia (CLI; Appendix, online only).
ICD-9 codes were selected based on experience from prior
studies.23,24
Patients with a documented code for AI (DUS, CTA,
or MRA), angiography, or expected angiography (endovas-
cular treatment without an additional imaging code) during
their inpatient admission were selected. Patients with a
double diagnosis of claudication and CLI were categorized
by the more severe diagnosis of CLI. The intent-to-treat
principle was used to categorize patients with codes for
both revascularization and amputation as revascularization
patients, and patients who received both AI and angio-
graphy were considered AI patients.
Our cohort was restricted to individuals aged
>40 years because the focus of this study was on patients
with adult-onset PAD. Those with diagnostic codes for
venous thrombosis, embolism in the lower extremity, or
pulmonary embolism (444.2, 453.4, 415.1) were excluded
from further analysis because they might have received
imaging for those indications rather than for assessment
of their PAD (n ¼ 52,671). Patients with a procedureday (any revascularization or amputation procedure) that
preceded the day of imaging were considered to have
received their imaging for follow-up and were excluded
because this study set out to assess the use of imaging mo-
dalities before treatment only (n ¼ 5539). Because clinical
scenarios and patterns of disease are different for claudi-
cant and CLI patients, we investigated AI distribution and
conducted multivariable analyses stratiﬁed by PAD type.
Statistical analysis. We analyzed the cohort to
compare demographics and hospital characteristics of
PAD patients receiving AI with those receiving angio-
graphy. Our primary end point was whether AI was
received. The secondary end point was AI utilization based
on rates of AI cases on an institutional and state level.
Patient comorbidities were controlled using the NIS
comorbidity software tool that assigns variables to identify
comorbidities based on hospital discharge ICD-9 coding.25
To summarize disease burden, vanWalraven risk scores were
used. These single numeric scores reﬂect association with
hospital death for a particular Elixhauser comorbid status.26
Utilization of imaging modalities was assessed over time,
and rates were analyzed using c2 testing.
For bivariate analyses of continuous variables and
dichotomous variables, t tests and c2 tests were used,
respectively. The Wilcoxon rank sum test for complex sur-
vey data was performed for comparison of the continuous
variables of length of stay and the van Walraven score.27
To assess the distribution of the various AI modalities
(DUS, CTA, and MRA), we conducted bivariate analysis
of individual AI modalities stratiﬁed by claudication or
CLI diagnosis. Factors associated with AI were identiﬁed
by using multivariable logistic regression for complex sur-
vey data (SURVEYLOG) while controlling for comorbid-
ities and hospital characteristics. This speciﬁc procedure
takes into account the NIS complex survey design,
including weight factors, sampling strata, and clustering
of patients within a hospital. Multivariable logistic regres-
sion was performed separately for claudicant and CLI
patients by using backward elimination until all remaining
variables were signiﬁcant at the a level of .05. In addition,
we investigated the association of speciﬁc treatment proce-
dures with AI in a subanalysis because these procedures
occur downstream of the workup process assessed in the
main analysis.
AI utilization across states was investigated on patient
and hospital level. First, the AI rate (AI cases/total cases
within a state) was calculated for each state. Second, this
AI rate was calculated for individual hospitals and subse-
quently averaged over all hospitals within a state to obtain
the mean AI rate of hospitals within a state. NIS is a nation-
wide sample of hospitals, and as a result, few hospitals in
some states are sampled. To minimize sample bias, our
state-level analysis excluded NIS data from states
with <500 patients who met inclusion criteria for our
study.
All analyses were performed using weighted data,
except for state measures, because survey weights are
created for weighing to a national level. An a level of
Fig. Rates of alternative imaging (AI) cases (%) in study cohort
during the years 2007 to 2010. CTA, Computed tomography
angiography; DUS, duplex ultrasound; MRA, magnetic resonance
angiography. The error bars show the standard error of the mean.
JOURNAL OF VASCULAR SURGERY
Volume 59, Number 5 de Vos et al 1317.05, corresponding to P ¼ .05, and 95% conﬁdence inter-
vals were used as criteria for statistical signiﬁcance. Data-
base linkages and analyses were conducted using SAS 9.3
software (SAS Institute Inc, Cary, NC).
RESULTS
Cohort. We identiﬁed 290,184 patients with a diag-
nostic code and procedure for PAD between 2007 and
2010. AI was used for 5702 patients (2.0%), and this study
compared them with the 284,464 patients who received
angiography. Within the AI group, DUS was the most
frequent modality used (3386 [59.2%]), followed by equal
rates of MRA (1474 [25.5%]) and CTA (1453 [25.4%]).
When stratiﬁed by diagnosis, DUS remained the most
prevalent type of AI for all PAD types but was more com-
mon among claudicant patients with AI than CLI patients
(72.3% vs 55.7%; P < .0001). For CLI patients, MRA took
up a notably larger portion of AI cases (30.7% vs 0.6%; P <
.0001), and CTA rates were lower than observed among
claudicant patients with AI (25.0% vs 27.1%; P < .0001).
Procedures and modalities over time. Over time, AI
utilization rates (6standard error) decreased slightly during
2007 to 2008 but rose after 2009 (2007: 2.36% 6 0.45%;
2008: 1.96% 6 0.37%; 2009: 1.60% 6 0.35%; 2010:
1.88% 6 0.38%; P ¼ .384). More speciﬁcally, we found
that MRA and DUS imaging rates decreased in our cohort
after 2007, whereas CTA numbers continued to rise over
the years, with only MRA numbers being signiﬁcantly
lower in later years (P ¼ .0008; Fig).
Demographics and comorbidities. Bivariate analysis
demonstrated that AI patients had signiﬁcantly more CLI
diagnoses and, consistent with this, fewer endovascular
procedures (48.4% vs 85.0%; P < .0001) and more open
revascularizations (30.4% vs 18.8%; P < .0001), minor am-
putations (25.9% vs 7.0%; P < .0001), and major amputa-
tions (14.7% vs 4.1%; P < .0001; Table I). Overall, patients
with AI had a higher comorbidity burden, as expressed by
van Walraven scores (5.85 6 0.22 vs 4.10 6 0.05; P <
.0001), and signiﬁcant differences in various comorbidities,including diabetes, renal failure (RF), and chronic heart
failure (CHF). Compared with angiography, AI utilization
rates were higher in patients of black race (20.6% vs 14.9%;
P < .0001) and in nonelective admissions (76.1% vs 37.6%;
P < .0001). The imaging groups were similar in age, sex,
and comorbid factors of other vascular disease, hyperten-
sion, and obesity.
Hospital factors. A signiﬁcant difference in AI use was
found among hospital regions (Table II). AI patients were
more often seen in hospitals in the Northeast and West and
less often in the Midwest or South regions (P < .0001).
Admission rates to teaching hospitals were signiﬁcantly
greater for AI patients (68.3% vs 49.8%; P ¼ .0001). In
addition, AI patients were more often admitted to a hos-
pital with a larger number of beds and a more urban
location than angiography patients; however, these hospital
characteristics were not signiﬁcantly associated with AI in
bivariate analysis.
Assessment on state level showed great variation in
rates of AI cases (Table III). Of the hospitals in our study
cohort, 78% reported zero AI cases. The remainder of hos-
pitals that did have AI cases were distributed among the
national regions as follows: Northeast, 25%; Midwest,
19%; South, 34%; and West, 21%. Even when states
with <500 patients in our sample were excluded, the over-
all rates of AI cases in states ranged from 0.31% to 9.81%.
When AI rates per hospital were averaged over all hospitals
within a state, these mean AI rates varied similarly from
0.08% to 9.76% across states.
Predictors of AI. After adjustment for patient and
hospital factors in multivariable analysis, we found that
geographic region remained associated with higher odds
that a claudicant patient would receive AI (Table IV).
Compared with the South, patients in the Northeast and
West were at increased odds of receiving AI (Northeast:
odds ratio [OR], 2.41; P ¼ .011; West: OR, 2.59; P ¼
.005). Other hospital factors that were associated with AI
were larger number of beds (medium: OR, 3.84; P ¼ .012;
large: OR, 3.28; P ¼ .025) or teaching status (OR, 1.97;
P ¼ .023). The only patient characteristic that stood out
for claudicant patients was a higher odds of AI for RF
patients (OR, 1.52; P ¼ .006) and for patients with a
nonelective admission (OR, 3.55; P < .0001).
For CLI patients, multivariable analysis controlling for
the same confounders demonstrated a similar effect of U.S.
hospital region on the likelihood of receiving AI (North-
east: OR, 4.31; P < .0001; West: OR, 2.18; P ¼ .021).
More patient factors were signiﬁcantly associated with AI
for CLI patients, including black race (OR, 1.53; P ¼
.006), CHF (OR, 1.29; P ¼ .021), and nonelective admis-
sion (OR, 3.89; P < .0001). In contrast to the claudicant
patients, RF in CLI patients was associated with a lower
odds of AI (OR, 0.80; P ¼ .012).
A subanalysis of the association of treatment proce-
dures with AI, controlling for the same factors as in former
analyses, demonstrated that in claudicant patients, endo-
vascular procedures were signiﬁcantly associated with lower
odds of AI (OR, 0.20; P < .0001), and higher odds of AI
Table I. Weighted frequencies of patient demographics for the total cohort, alternative imaging (AI), and angiography
patients
Variablea Cohort AI Angiography Pb
Patients 290,184 (100) 5720 (2) 284,464 (98)
Age, years 69.87 6 0.11 69.74 6 0.62 69.88 6 0.11 .820
Female sex 128,969 (44.0) 2491 (43.5) 126,478 (44.5) .530
Racec .0001
White 169,179 (71.9) 3050 (60.2) 166,129 (72.1)
Black 35,263 (15.0) 1045 (20.6) 34,218 (14.9)
Hispanic 19,786 (8.4) 678 (13.4) 19,108 (8.3)
Other 11,158 (4.7) 294 (5.8) 10,864 (4.7)
Diagnosis
Claudication 147,320 (50.8) 1214 (21.2) 146,106 (51.4) <.0001
CLI 142,863 (49.2) 4505 (78.8) 138,358 (48.6)
Admission
Nonelective 110,922 (38.4) 4350 (76.1) 106,572 (37.6) <.0001
Length of stay, days 5.13 6 0.11 12.55 6 0.61 4.98 6 0.10 <.0001
Procedure type
Revascularization 280,221 (96.6) 4232 (74.0) 275,990 (97.0) <.0001
Amputation only 9963 (3.4) 1488 (26.0) 8474 (3.0)
Procedured
Endovascular 244,699 (84.4) 2766 (48.4) 241,933 (85.0) <.0001
Open 55,311 (19.0) 1740 (30.4) 53,571 (18.8) <.0001
Minor amputation 21,394 (7.4) 1481 (25.9) 19,914 (7.0) <.0001
Major amputation 12,604 (4.3) 839 (14.7) 11,765 (4.1) <.0001
Comorbidities
van Walraven scoree 4.14 6 0.05 5.85 6 0.22 4.10 6 0.05 <.0001
RF 60,550 (20.9) 1522 (26.6) 59,028 (20.8) .0001
Other vascular disease 114,233 (39.4) 2403 (42.0) 111,830 (39.3) .241
Diabetesf 123,067 (42.4) 2821 (49.3) 120,246 (42.3) <.0001
Hypertensiong 218,909 (75.4) 4357 (76.2) 214,552 (75.4) .611
CHF 21,767 (7.5) 777 (13.6) 20,989 (7.4) <.0001
Obesity 16,672 (5.7) 346 (6.1) 16,326 (5.7) .677
CHF, Chronic heart failure; CLI, critical limb ischemia; RF, renal failure.
aCategoric data are presented as number (%) and continuous data are presented as mean 6 standard error.
bTests for signiﬁcance: c2 for dichotomous variables, t-test for age, and Wilcoxon rank sum for length of stay and van Walraven risk score.
cRace was missing for 54,799 patients (18.9%), 653 AI patients (11.4%), and 54,146 angiography patients (18.1%).
dMore than one treatment or AI procedure can be documented on the patient discharge record.
eThe van Walraven risk score is a single numeric score to summarize burden of disease based on Elixhauser comorbidity scores that can range
from 19 to þ89.
fIncluded diabetes with and without complications.
gAll hypertension patients in our cohort had a documented diagnosis of hypertension with complications.
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P < .0001). In CLI patients, odds of AI were signiﬁcantly
lower with endovascular (OR, 0.18; P < .0001) and open
procedures (OR, 0.48; P < .0001).DISCUSSION
This study assessed the role of AI in the care of patients
with PAD and found low frequencies for the AI modalities
compared with angiography. National estimates on the use
of the imaging modalities in PAD have not yet been
reported, although the national estimates for numbers of
PAD cases in this study are consistent with prior publica-
tion.23 We observed a slight downward trend for MRA,
which could be associated with the warnings issued in
2006 and 2007 by the U.S. Federal Drug Administration
against the gadolinium-based contrast agents used in
MRA (Fig).28 These gadolinium-based contrast agents
were found to be associated with the rare but potentiallyfatal complication of nephrogenic systemic ﬁbrosis in pa-
tients with renal disease.
Regional and institutional variation. AI utilization is
subject to signiﬁcant regional variation and is positively
associated with the U.S. Northeast and West regions.
State-level results furthermore demonstrate the institu-
tional and regional disparities in AI utilization. The hospital
factors of larger bed size and teaching status were associ-
ated with AI in care of claudicant patients. These ﬁndings
indicate differences in systems of care and practice patterns.
Lack of available AI devices is not likely to be a major factor
in the contemporary paucity of AI utilization found in this
study. Financial drivers can potentially play a role in insti-
tutional variation because incentives can be different for
vascular surgeons in private practice models than for those
who are hospital-based and salaried.
Patient factors. Frequencies of AI were higher among
CLI patients compared with claudicant patients in our
cohort. To understand this, we can examine the different
Table II. Weighted frequencies of hospital types for
alternative imaging (AI) and angiography patients
Variable
AI (n ¼ 5720),
No. (%)
Angiography
(n ¼ 284,464),
No. (%) P
Bed sizea
Small 257 (4.5) 26,244 (9.3) .214
Medium 1311 (23.0) 59,640 (21.1)
Large 4134 (72.5) 196,651 (69.6)
Teaching status
Nonteaching 1806 (31.7) 141,714 (50.2) .001
Teaching 3897 (68.3) 140,821 (49.8)
Location
Rural 305 (5.4) 23,281 (8.2) .157
Urban 5397 (94.6) 259,254 (91.8)
Region
Northeast 2532 (44.3) 53,336 (18.7) <.0001
Midwest 988 (17.3) 75,260 (26.5)
South 1202 (21.0) 110,720 (38.9)
West 998 (17.4) 45,147 (15.9)
aThe Nationwide Inpatient Sample (NIS) has assigned hospital bed size
categories speciﬁc to the hospital’s location and teaching status, and infor-
mation was obtained from the American Hospital Association Annual Sur-
vey of Hospitals.31
Table III. Variability of state alternative imaging (AI)
utilization sorted by overall AI rates (AI cases/total cases
per state)
Region State
Overall
AI ratea
Mean AI
rate of hospitalsb
Northeast NY 9.81 9.52
NJ 2.33 7.22
Mec 2.27 25.00
Vtc 1.75 1.75
Conn 1.30 0.64
RIc 1.22 2.38
Mass 1.11 0.39
Pa 1.09 2.13
NHc 0.34 0.07
Midwest Mich 3.48 1.84
Ill 2.01 1.59
Minn 1.02 3.56
Ohio 1.02 4.63
Ind 0.97 2.46
Iowa 0.41 0.86
Mo 0.32 3.21
Wisc 0.32 0.08
Kanc 0.28 0.44
Nebc 0.27 0.30
SDakc 0 0
West Montc 16.67 9.26
Hawaiic 3.82 2.22
Calif 3.38 7.42
Orec 1.16 1.17
Colo 0.78 1.28
Wash 0.71 2.10
Ariz 0.57 1.41
Nevc 0.29 0.10
NM, Utah, Wyoc 0 0
South SC 3.53 9.12
Md 3.32 9.76
Fla 1.87 1.25
Va 1.04 4.97
Ga 1.03 2.94
NC 0.87 0.54
Missc 0.74 2.08
Ky 0.72 2.47
Tex 0.55 0.71
WV 0.48 0.43
La 0.43 1.76
Ark 0.37 0.71
Okla 0.36 0.25
Tenn 0.34 1.97
aOverall AI rate (%): number of AI cases/the number of total cases within a
state.
bMean AI rate of hospitals (%): AI rates are calculated, in the same fashion, for
individual hospitals and subsequently averaged over all hospitals in the state.
cAll states contributed >500 patients to our cohort with the exception of
these marked states. Availability in Nationwide Inpatient Sample (NIS):
Pennsylvania and Louisiana since 2008; New Mexico and Montana since
2009; New Hampshire until 2009; and Mississippi since 2010. North
Dakota, Alabama, Delaware, District of Columbia, and Idaho are not par-
ticipants in NIS. Alaska was added to NIS in 2010 but was not sampled by
our cohort.
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treatment in the decision-making process. For example,
CLI patients with worse clinical or comorbid status (such
as CHF seen in our study) and higher likelihood of
amputation upon presentation may get more AI to avoid
the additional invasiveness of the diagnostic test of angio-
graphy and to avoid performing to invasive procedures.
This is consistent with the increased odds of AI found for
nonelective admissions and for patients of minority race,
who are documented to already have worse outcomes for
PAD in the vascular surgical literature.29
The study cohort consisted of only patients who
received PAD treatment or amputation and excluded pa-
tients who were managed conservatively. Our ﬁnding of
higher rates of angiography for claudication patients might
be due to the greater potential of concurrent endovascular
treatment with diagnostic angiography. AI patients might
be more likely to undergo surgery because those who
received angiography might have received concurrent ther-
apy that removed the need for surgery.
We found that RF was positively associated with AI
among claudicant patients but negatively associated with
AI among CLI patients. This ﬁnding can be understood
when examining the alternative to AI among these patient
groups. For CLI patients with RF, angiography may be a
better choice compared with the risk of nephrogenic sys-
temic ﬁbrosis from MRA or poor distal visualization from
DUS.
This study, similar to many studies in this ﬁeld, is
limited by its retrospective nature and depends on the accu-
racy of the hospital administrative data and consistency of
ICD-9 coding among U.S. regions and institutions to
identify which imaging modality patients received. Vari-
ability in the accuracy of discharge data and under-reporting have both been described.30 Also, NIS data
lack the granularity needed to fully assess the decision-
making processes and rationale in diagnostic strategy,
including the indication for which the imaging was per-
formed and the overall rationale for diagnostic strategy of
Table IV. Multivariable results for receiving alternative imaging (AI) stratiﬁed by diagnosis of claudication and critical
limb ischemia (CLI)
Variable
Claudicationa
Variable
CLIb
OR (95% CI) P OR (95% CI) P
Hospital region Hospital region
Northeast 2.41 (1.23-4.75) .011 Northeast 4.31 (2.20-8.36) <.0001
Midwest 1.77 (0.79-3.96) .166 Midwest 1.31 (0.57-3.00) .528
West 2.59 (1.34-5.02) .005 West 2.18 (1.12-4.22) .021
South Reference . South Reference .
Nonelective admission 3.55 (2.56-4.93) <.0001 Nonelective admission 3.89 (2.98-5.05) <.0001
RF 1.52 (1.13-2.05) .006 RF 0.80 (0.67-0.95) .012
Hospital bed size . Race
Small Reference .012 White Reference .
Medium 3.84 (1.35-10.92) .025 Black 1.53 (1.13-2.08) .006
Large 3.26 (1.16-9.18) Hispanic 1.50 (0.96-2.36) .078
Teaching hospital 1.97 (1.10-3.52) .023 Other 1.24 (0.90-1.70) .187
Age 0.99 (0.98-0.996) .002
CHF 1.29 (1.04-1.60) .021
CHF, Chronic heart failure; CI, conﬁdence interval; OR, odds ratio; RF, renal failure.
Backward elimination model included: age, sex, race, diabetes, complicated hypertension, RF, other peripheral vascular disease, CHF, obesity, admission type,
and hospital characteristics (bed size, teaching status, location, and region).
aModel C statistic: 0.731.
bModel C statistic: 0.753.
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ing diagnosis of pulmonary embolism or venous thrombosis
because we felt it was too likely that they received imaging
for these other diagnoses rather than for their PAD.
For several reasons, we performed separate analyses for
claudicant and CLI patients. Claudicant and CLI patients
have different risk factors, undergo different treatments,
and have different rates of amputation and mortality. The
setting of treatment for these two groups also differs,
because claudicant patients undergoing endovascular treat-
ment are more likely to be outpatients not captured in NIS.
We recognize the lack of outpatient data as an important
limitation of this study on utilization of AI modalities.
Fortunately, this will be less problematic for our analysis
of CLI patients because Sachs et al23 have shown that
only a small number of these treatments occur as an outpa-
tient (1.3% of total inpatient charges for CLI), and thus,
outpatient treatment procedures for CLI do not have a ma-
jor effect on national overall estimates. Nonetheless, pa-
tients who receive outpatient imaging in another or
outpatient admission separate from inpatient treatment,
such as CLI patients with a long preceding work-up for
their PAD, would not be included in our inpatient data
analysis. We speculate that AI (compared with angio-
graphy) is more likely to occur as an outpatient testing
procedure, and thus, it is possible that our AI ﬁndings
underestimate overall AI utilization. However, the use of
angiography or AI as an outpatient imaging modality sepa-
rate from inpatient treatment is not well known and thus
potential bias on this matter is not certain.
Future directions. These limitations notwithstanding,
we found that the likelihood a patient will receive AI de-
pends on a complex array of factors, including status of
the patient and also institutional factors. Availableresources or local expertise can only partially explain the in-
ﬂuence of hospital factors; nonetheless, we found signiﬁ-
cant regional and institutional variation in practice
patterns. Additionally, there are likely as yet unidentiﬁed
and underlying factors and processes, including individual
or institutional preferences and conﬁdence in AI results,
that drive the speciﬁc diagnostic strategy formulated for
the PAD patient. We suspect that differences in reimburse-
ment rates for imaging modalities as well as differences in
who receives these reimbursements can also affect imaging
choices.
Despite the existing evidence supporting the beneﬁts of
AI use in PAD, our results show a relative sparse national
utilization of AI modalities and broad institutional varia-
tion. This may warrant a clearer understanding of the
role of various imaging modalities in the workup for
PAD care. Because no other national study is available to
address this question of AI utilization, further research
would be required to better understand underlying drivers
of individual and institutional preference that inﬂuence this
process of care and to address these questions with the in-
clusion of outpatient data.
To tailor the appropriate diagnostic strategy to each in-
dividual patient, we need to understand the tradeoffs, the
merits, and the limitations of each imaging modality and
identify subgroups of patients to individualize the diag-
nostic strategy in care of PAD. We also need to identify
and overcome other barriers of AI utilization, including
lack of conﬁdence in AI results or over-reliance on familiar-
ity of angiography as the only imaging modality. It is
important to balance the conﬂicting aspects of detail and
clarity of the resulting images vs invasiveness for the patient
to choose the least harmful but sufﬁciently informative im-
aging modality. Ultimately, we advocate for a practical
JOURNAL OF VASCULAR SURGERY
Volume 59, Number 5 de Vos et al 1321decision algorithm to help clinicians identify patients for
whom they can conﬁdently choose a less invasive, but
informative diagnostic modality.
CONCLUSIONS
This study demonstrates that national utilization of AI
is low and that variability in diagnostic strategy in inpatient
care of PAD exists. Besides the clinical status of the patient,
institutional and regional factors are also associated with
the imaging modality PAD patients receive. The results
reveal that cases with AI are not evenly distributed but
are clustered in the Northeast and West U.S. regions or,
for claudication, in larger and teaching hospitals. A better
understanding of practice variability and underlying clinical
and institutional cultures and preferences is key to creating
a more uniﬁed approach to imaging strategy in PAD care.
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Volume 59, Number 5 de Vos et al 1322.e1APPENDIX (online only). International Classiﬁcation of Diseases-Ninth Edition(ICD-9) codes used for peripheral
arterial disease (PAD) diagnoses and proceduresICD-9 code Description
PAD diagnoses
Claudication
440.20 Atherosclerosis of native arteries of the extremities, unspeciﬁed
440.21 Atherosclerosis of native arteries of the extremities, with intermittent claudication
443.9 Peripheral vascular disease
CLI
440.22 Atherosclerosis of native arteries of the extremities with rest pain
440.23 Atherosclerosis of native arteries of the extremities with ulceration
440.24 Atherosclerosis of native arteries of the extremities with gangrene
707.1 Ulcer of the lower limbs, except decubitus
707.10 Ulcer of the lower limbs, unspeciﬁed
707.11 Ulcer of thigh
707.12 Ulcer of calf
707.13 Ulcer of ankle
707.14 Ulcer of heel and midfoot
707.15 Ulcer of other part of foot
707.19 Ulcer of other part of lower limb
PAD procedures
Revascularization
Open
39.25 Aorto-iliac femoral bypass
39.29 Peripheral bypass
Endovascular
39.50 Angioplasty or atherectomy of non-coronary vessel
39.90 Insertion of non-drug-eluting, non-coronary artery stent(s)
Amputation
Minor
84.11 Amputation of toe
84.12 Amputation through foot
Major
84.13 Disarticulation of ankle
84.14 Amputation of ankle through malleoli of tibia and ﬁbula
84.15 Other amputationdbelow ankle
84.16 Disarticulation of knee
84.17 Amputationdabove knee
Imaging
Angiography
88.48 Arteriography of femoral and other lower extremity arteries
88.40 Arteriography using contrast material, unspeciﬁed site
17.71 Non-coronary intra-operative ﬂuorescence vascular angiography (IFVA)
AI
DUS
88.77 Diagnostic ultrasound of peripheral vascular system
00.03 Therapeutic ultrasound of peripheral vascular vessels
CTA
88.01 Computerized axial tomography of abdomen
88.38 Other computerized axial tomography
MRA
88.94 Magnetic resonance imaging of musculoskeletal
88.97 Magnetic resonance imaging of other unspeciﬁed sites
AI, Alternative imaging; CLI, critical limb ischemia; CTA, computed tomography angiography; DUS, duplex ultrasound;MRA, magnetic resonance imaging.
